All In Biotech

Drug Trial Radar · NCT00042458

Evaluation of Dose-titration of Pramlintide During Initiation of Therapy in Patients Trying to Improve Glucose Control

A Randomized, Triple-Blind, Placebo-Controlled, Multicenter Study to Investigate the Safety of Pramlintide Treatment Employing Pramlintide Dose-Titration Followed by Insulin Dose Optimization in Subjects With Type 1 Diabetes Mellitus Who Have Not Achieved Glycemic Targets With Intensive Insulin Therapy

Last checked: Nov 20, 2026Latest source record: Sep 23, 2015 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 296 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

296

Actual

Start

Apr 2002

Primary completion

Mar 2003

Study completion Mar 2003

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
First posted
Aug 1, 2002

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Single group
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a randomized, triple-blind, placebo-controlled, multicenter study to investigate the safety of pramlintide treatment using pramlintide dose-titration coupled with insulin adjustments in subjects with type 1 diabetes who are actively trying to improve their glycemic control.

Conditions

  • Diabetes Mellitus, Type 1

Interventions

  • Pramlintide acetateDrug

    Pramlintide injection will be supplied in 5-mL multidose glass vials with rubber stoppers.

  • PlaceboDrug

    The placebo injection will be supplied in the same 5-mL multidose glass vials with a rubber stopper.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. - To investigate the safety of pramlintide treatment employing dose titration upon initiation of pramlintide followed by insulin dose optimization in subjects with type 1 diabetes.Time frame: 29 Weeks

Locations

33 sites in 1 country. Site status is shown where the registry gives one.

  • Ana Ventures LLC

    Mesa, Arizona

  • Phoenix Endocrinology Clinic, Ltd.

    Phoenix, Arizona

  • East Bay Clinical Trial Center

    Concord, California

  • Valley Research

    Fresno, California

  • UCSD Diabetes Research Center

    San Diego, California

  • Diabetes Research Institute

    San Mateo, California

  • Sansum Medical Research Institute

    Santa Barbara, California

  • Diablo Clinical Research

    Walnut Creek, California

  • Barbara Davis Center for Childhood Diabetes

    Denver, Colorado

  • MedStar Clinical Research Center

    Washington D.C., District of Columbia

  • Medical Research Unlimited

    Aventura, Florida

  • Medical Research Unlimited

    Aventura, Florida

  • Internal Medicine Associates

    Fort Myers, Florida

  • Suncoast Clinical Research

    New Port Richey, Florida

  • Children's Clinic

    Tallahassee, Florida

  • Atlanta Diabetes Associates

    Atlanta, Georgia

  • St. James Diabetes Center

    Chicago Heights, Illinois

  • St. James Diabetes Center

    Chicago Heights, Illinois

  • Indiana University Outpatient Clinical Research

    Indianapolis, Indiana

  • University of Maryland Joslin Diabetes Center

    Baltimore, Maryland

  • Henry Ford Health System

    Detroit, Michigan

  • Grand Rapids Associated Interns

    Grand Rapids, Michigan

  • Radiant Research

    St Louis, Missouri

  • Mercury Street Medical

    Butte, Montana

  • UNC Diabetes Care Center

    Durham, North Carolina

  • Ohio State Univ.-Division of Endocrinology, Diabetes

    Columbus, Ohio

  • Radiant Research

    Portland, Oregon

  • Physicians for Clinical Research

    Camp Hill, Pennsylvania

  • Vanderbilt University Medical Center

    Nashville, Tennessee

  • North Texas Clinical Research

    Irving, Texas

  • Private Practice

    Lufkin, Texas

  • Private Practice

    Lufkin, Texas

  • Rainier Clinical Research Center

    Renton, Washington

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.